Circulating tumor cells in patients with breast cancer: Monitoring chemotherapy success

In Vivo

Volumn 28, Issue 4, 2014, Pages 605-614

  Ušiaková, Zuzana ^a   Mikulová, Veronika ^a   Pintérová, Daniela ^b   Brychta, Milan ^c   Valchář, Josef ^c   Kubecová, Martina ^c   Tesařová, Petra ^a   Bobek, Vladimír ^c,d   Kološtová, Katarína ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Breast cancer; Chemotherapy; Circulating tumor cells; CTC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; HORMONE RECEPTOR; MUCIN 1; TUMOR MARKER;

ADULT; ARTICLE; BONE MARROW EXAMINATION; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CAPILLARY ELECTROPHORESIS; CELL ISOLATION; CIRCULATING TUMOR CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; TREATMENT RESPONSE; TUMOR MARKER RAPID TEST; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CANCER GRADING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TUMOR EMBOLISM; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84918525655     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791, 2004.
2. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN et al: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23: 1420-1430, 2005.
3. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R and Kasimir-Bauer S: Detection and characterization of circulating tumor cells in blood ofprimary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11: R59, 2009.
4. Giordano AI, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM and Cristofanilli M: Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2- positive disease treated with targeted therapy. Ann Oncol 23(5): 1144-1150, 2012.
5. Giuliano MI, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN,Reuben JM and Cristofanilli M: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 213: R67, 2011.
6. Ignatiadis M, Georgoulias V and Mavroudis D: Circulating tumor cells in breast cancer. Curr Opin Obstet Gynecol 20: 55-60, 2008.
7. Meng SI, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D,Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J and Uhr JW: irculating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10: 8152-8162, 2004.
8. Criscitiello C, Sotiriou C and Ignatiadis M: Circulating tumor cells and emerging blood biomarkers in breast cancer. Curr Opin Oncol 22: 552-558, 2010.
9. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV and Terstappen LW: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progressionfree and overall survival. Clin Cancer Res 12: 4218-4224, 2006.
10. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904, 2004.
11. Lankiewicz S, Rivero BG and Bocher O: Quantitative real-time RTPCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol Biotechnol 34: 15-27, 2006.
12. Hauch S, Zimmermann S, Lankiewicz S, Zieglschmid V, Bocher O and Albert WH: The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res 27: 1337-1341, 2007.
13. Graves H and Czerniecki BJ: Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression. Patholog Res Int 2011: 621090, 2011.
14. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V and Mavroudis D: Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25: 5194-5202, 2007.
15. Zhao S, Liu Y, Zhang Q, Li H, Zhang M, Ma W, Zhao W, Wang J and Yang M: The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. Breast Cancer Res Treat 130: 809-816, 2011.
16. Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G and Zanker KS: Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer 76: 824-828, 1998.
17. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L and Brandt B: HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.Clin Cancer Res 12: 1715-1720, 2006.
18. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumormarkers in breast cancer. J Clin Oncol 25(33): 5287-5312, 2007.
19. Puglisi F, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F, Gori S and Del Mastro L: Follow-up of patients with early breast cancer: Is it time to rewrite the story? Crit Rev Oncol Hematol Mar 22. pii: S1040-8428(14)00050-X. doi: 10.1016/j.critrevonc.2014.03.001, 2014.
20. Litière S, de Vries EG, Seymour L, Sargent D, Shankar L and Bogaerts J;The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.Eur J Cancer Apr 10. pii: S0959-8049(14)00269-X. doi: 10.1016/j.ejca.2014.03.014, 2014 .
21. Ignatiadis M, Georgoulias V and Mavroudis D: Micrometastatic disease in breast cancer: clinical implications. Eur J Cancer 44: 2726-2736, 2008.
22. Mikulova V, Kolostova K and Zima T: Methods for detection of circulating tumour cells and their clinical value in cancer patients. Folia Biol (Praha) 57: 151-61, 2011.
23. Kolostova K, Pinterova D, Hoffman RM and Bobek V.: Circulating human prostate cancer cells from an orthotopic mouse model rapidly captured by immunomagnetic beads and imaged by GFP expression. Anticancer Res 31: 1535-1539, 2011.
24. Menen RS, Pinney E, Kolostova K, Bobek V, Suetsugu A, Zhang N, Bouvet M and Hoffman RM: A rapid imageable in vivo metastasis assay for circulating tumor cells. Anticancer Res 31: 3125-3128, 2011
25. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V and Mavroudis D: Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27: 2177-2184, 2009.
26. Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM and Naume B: Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 118: 2013-2019, 2006.
27. Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E and Georgoulias V: Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res 23: 1883-1890, 2003.
28. Rack B, Andergassen U, Neugebauer J, Salmen J, Hepp P, Sommer H, Lichtenegger W, Friese K, Beckmann MW, Hauner D, Hauner H and Janni W: The German SUCCESS C Study -the first European lifestyle study on breast cancer. Breast Care 5: 395-400, 2010.
29. Pierga JY, Bonneton C, Magdelenat H, Vincent-Salomon A, Nos C, Pouillart P and Thiery JP: Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br J Cancer 89: 539-545, 2003.
30. Jotsuka T, Okumura Y, Nakano S, Nitta H, Sato T, Miyachi M, Suzumura K and Yamashita J: Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery 135: 419-426, 2004.
31. Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C,Perraki M, Sivridis E and Georgoulias V: Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int J Cancer 108: 620-627, 2004.
32. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez M, Campos M, de la Torre N, Algarra I, Duenas R and Lozano A: Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 107: 984-990, 2003.
33. Demel U, Tilz GP, Foeldes-Papp Z, Gutierrez B, Albert WH and Bocher O: Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay. J Exp Clin Cancer Res 23: 465-468, 2004.
34. Benoy IH, Elst H, Philips M, Wuyts H, van DP, Scharpe S, Van ME, Vermeulen PB and Dirix LY: Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 94: 672-680, 2006.
35. Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, Casadio C, Botteri E, Rotmensz N, Adamoli L and Nole F: Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 17: 1539-1545, 2010.
36. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De 37. Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY and Michiels S: Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15(4): 406-414, 2014.
37. Giordano A and Cristofanilli M: CTCs in metastatic breast cancer.Recent Results Cancer Res 195: 193-201, 2012.
38. Giuliano M1, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM and Cristofanilli M: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13(3): R67, 2011.
39. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R and Kasimir-Bauer S: Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115: 581-590, 2009.
40. Mayer JA, Pham T, Wong KL, Scoggin J, Sales EV, Clarin T, Pircher TJ, Mikolajczyk SD, Cotter PD and Bischoff FZ: FISHbased determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE platform. Cancer Genet 204: 589-595, 2011.
41. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L,Giannini A andDi LA: Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118: 523-530, 2009.
42. Tokudome N1, Ito Y, Takahashi S, Kobayashi K, Taira S, Tsutsumi C, Oto M, Oba M, Inoue K, Kuwayama A, Masumura K, Nakayama Y, Watanabe C and Hatake K: Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients. Breast Cancer 18: 195-202,2011.
43. Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C,Stathopoulos E, Georgoulias V and Mavroudis D: Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat 117: 525-534, 2009.
44. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de CP, Marty M and Pierga JY: Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 21: 729-33, 2010.
45. Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ and Naume B: The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res 13: R61, 2011.